At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 80 enrolled
Drug / intervention
CC-42344 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Ascending and Multiple-Ascending Doses of the Influenza A Virus Replication Inhibitor CC-42344
In Brief
A Phase 1 clinical trial evaluating CC-42344 and Placebo for Influenza A. Completed, enrolled 80 participants across 1 site.
Detailed Summary
CC-42344 Phase 1 study with single-ascending dose (SAD) and multiple-ascending dose (MAD) parts.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza A
CountriesAustralia
CollaboratorsCocrystal Pharma Australia Pty Ltd., Linear Clinical Research
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedJan 2022
Enrollment StartFeb 2022
Primary CompletionMar 2023
TodayJul 2026
First PostedJan 21, 2022
Enrollment StartFeb 11, 2022
Primary CompletionMar 29, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.4 years ago
Interventions
CC-42344drug
CC-42344 capsules
Placebodrug
Placebo capsules